BioMarin Pharmaceuticals
BMRN
559 hedge funds and large institutions have $10.4B invested in BioMarin Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 92 funds opening new positions, 214 increasing their positions, 163 reducing their positions, and 67 closing their positions.
44% more call options, than puts
Call options by funds: $96M | Put options by funds: $66.6M
38% more funds holding in top 10
Funds holding in top 10: 8 → 11 (+3)
37% more first-time investments, than exits
New positions opened: 92 | Existing positions closed: 67
31% more repeat investments, than reductions
Existing positions increased: 214 | Existing positions reduced: 163
4% more funds holding
Funds holding: 539 → 559 (+20)
2.46% less ownership
Funds ownership: 97.96% → 95.5% (-2.5%)
7% less capital invested
Capital invested by funds: $11.2B → $10.4B (-$812M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$184M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$101M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$79.5M |
| 4 |
Viking Global Investors
Stamford,
Connecticut
|
+$59.8M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
+$57.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Squarepoint
New York
|
-$85.6M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$67.1M |
| 3 |
Morgan Stanley
New York
|
-$58M |
| 4 |
Pacer Advisors
Malvern,
Pennsylvania
|
-$53.3M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$50.5M |
BMRN Hedge Fund Activity: Q1 2026 in Review
559 of the 8,187 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q1 2026, worth a combined $10.4B — down 7.3% from $11.2B a quarter earlier.
Buyers outnumbered sellers: 92 funds opened new BMRN positions and 67 closed out — a net gain of 25 holders — while 214 added to existing stakes and 163 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $184M. The largest seller was Squarepoint, cutting an estimated $85.6M.
- 559 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q1 2026, up from 539 in Q4 2025.
- Funds reported $10.4B of BioMarin Pharmaceuticals stock for Q1 2026, down 7.3% quarter-over-quarter.
- 92 funds opened new BioMarin Pharmaceuticals positions in Q1 2026 and 67 closed out, a net change of +25 holders.
- The largest BioMarin Pharmaceuticals buyer in Q1 2026 was Citadel Advisors, an estimated $184M added.
- The largest BioMarin Pharmaceuticals seller in Q1 2026 was Squarepoint, an estimated $85.6M sold.
Based on aggregated 13F filings for Q1 2026.